China Medical System Wins Desidustat Approval Raising Nephrology Growth Questions

• China Medical System Holdings (SEHK:867) has received marketing approval in China for Desidustat Tablets, an oral treatment for renal anaemia in non dialysis chronic kidney disease patients.
• The approval adds a new drug to the company’s nephrology portfolio and targets a major unmet medical need in China.

China Medical System Holdings is drawing fresh attention after this new approval, with the share price at HK$13.49 and a 1 year return of 81.4%. The stock has also seen a 6.1% gain over the past week, despite a 12.0% decline over the past 30 days, which may catch the eye of investors watching shorter term moves.

For investors tracking SEHK:867, Desidustat Tablets adds another product to the company’s pipeline in a focused therapeutic area. How the launch progresses and how the drug fits into existing treatment options could be important factors to watch as the nephrology business develops.

Stay updated on the most important news stories for China Medical System Holdings by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on China Medical System Holdings.

📰 Beyond the headline: 0 risks and 3 things going right for China Medical System Holdings that every investor should see.

Desidustat’s approval gives China Medical System Holdings another nephrology product that can sit alongside Velphoro and potentially deepen its presence with kidney specialists. The drug targets renal anaemia in non dialysis chronic kidney disease patients, an area where treatment rates in China are described as low relative to the size of the patient pool. Because Desidustat is an oral HIF-PHI, it may appeal where injectable therapies are less convenient, which matters for long term adherence and for patients treated outside major dialysis centers. For you as an investor, the key questions are how quickly the company can convert its specialist network into prescribing volume and how pricing and reimbursement terms are set, especially with other HIF-PHIs marketed globally by groups such as AstraZeneca, GlaxoSmithKline and Akebia Therapeutics. The company recently reported C¥8,212.06m of sales and C¥1,488.89m of net income for 2025, so any contribution from Desidustat will build on an already meaningful revenue base. Management also highlights a broader pipeline with multiple drugs approved or under review, so this launch sits within a wider push to expand the nephrology franchise rather than a one off event.

The Risks and Rewards Investors Should Consider

• ⚠️ Execution risk around uptake, including how quickly doctors switch from established anaemia treatments and how reimbursement decisions affect real world demand.
• ⚠️ Competitive pressure from other anaemia therapies and potential pricing constraints that could limit the profitability of Desidustat in a crowded CKD market.
• 🎁 Expanded nephrology portfolio that can leverage existing expert relationships and distribution channels built around Velphoro to support cross selling.
• 🎁 Exposure to a large CKD anaemia patient pool in China, where treatment coverage is described as relatively low for non dialysis patients, providing scope for higher prescription volumes if the drug is well received.

What To Watch Going Forward

From here, focus on a few practical markers. First, watch for management commentary on early prescription trends and hospital or clinic listings for Desidustat, which can indicate how fast uptake is building. Second, track any disclosures on pricing, reimbursement approvals and whether the drug enters key insurance lists, since those details often influence real volume. Third, monitor how the nephrology segment is described in future results and whether management attributes a clear share of revenue to Desidustat as the product matures.

To stay updated on how the latest news shapes the investment narrative for China Medical System Holdings, visit the community page for China Medical System Holdings to follow key community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com